Latest Articlesddd
The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus We like the fact that Ventyx …
Intellia Therapeutics Intellia Therapeutics (NTLA) announced that the U.S. FDA has cleared the company’s Investigational New …
Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. (APLS) is a biopharma firm developing novel products for debilitating and …
The Bear Market The volatility in the Bear stock market continues to plunge the values of …
Prohost's Beliefs About the Status of the Market That the market is still volatile and Bear. …
Endogena Therapeutics The US FDA designated Fast Track development program for the investigation of Endogena Therapeutics' …
Xenon Pharmaceuticals Xenon Pharmaceuticals (XENE) - a clinical stage biopharmaceutical company developing novel treatments aimed at improving …
Merck KEYTRUDA Announcement Merck (MRK) announced today that Phase 3 NRG-GY018 trial evaluating KEYTRUDA in combination …
CytomX Therapeutics We posted several articles that brought good news from CytomX Therapeutics (CTMX), yet the …
It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. …
XyloCor Therapeutics Announced Positive Results for XC001 XyloCor Therapeutics announced the completion of the Phase 2 portion …
TG Therapeutics TG Therapeutics (TGTX) is a commercial stage, biopharmaceutical company developing and commercializing novel treatments for …
Jazz Pharmaceuticals and Zymeworks Inc Announce Results of Zanidatamab Jazz Pharmaceuticals (JAZZ) and Zymeworks Inc. (ZYME)
Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise Editas Medicine, Inc. (EDIT), announced that it has …
Ionis Pharmaceuticals and Royalty Pharma Ionis Pharmaceuticals (IONS) and Royalty Pharma plc (RPRX) announced that Royalty Pharma has …
CureVac N.V. in the News CureVac N.V. (CVAC) announced that after more than 10 years as …
CytomX and Moderna in the NEWS On January 05, 2023, CytomX Therapeutics (CTMX) and Moderna Inc (MRNA) announced a collaboration …
January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata …
The Stock Market in the New Year It is still too early to tell how the …
Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
